Oklahoma 2024 Regular Session

Oklahoma Senate Bill SB217

Introduced
2/6/23  

Caption

Health care; requiring licensed practitioners to offer pharmacogenomic test prior to prescription of psychotropic drugs. Effective date.

Impact

The implication of SB217 is significant for both healthcare providers and patients. By requiring pharmacogenomic testing, the bill aims to enhance patient safety and treatment efficacy in psychiatric care. It could lead to a more personalized approach in medication management, as practitioners will have a better understanding of how different individuals metabolize drugs. However, it also raises questions about the accessibility of such tests and whether all practitioners will be adequately trained to interpret the results of pharmacogenomic assessments.

Summary

Senate Bill 217 is a new piece of legislation introduced in the State of Oklahoma that mandates licensed healthcare practitioners to offer pharmacogenomic testing prior to prescribing any psychotropic drugs to patients. The bill emphasizes the significance of understanding how a patient's genetic makeup might influence their response to medications, thus guiding practitioners in making informed prescribing decisions. This proactive step is intended to optimize treatment plans and potentially minimize adverse effects associated with psychotropic medication.

Contention

While proponents of SB217 advocate for the potential benefits of personalized medicine, there are concerns about the practical aspects of implementation. Some critics may argue about the costs associated with pharmacogenomic testing and whether insurance plans will cover such tests. Additionally, there are discussions surrounding patient privacy and the ethical implications of genetic testing, particularly regarding the handling of sensitive genetic information. Hence, while the bill has the potential to improve healthcare outcomes, it necessitates a thorough examination of its operational feasibility and ethical considerations.

Companion Bills

OK SB217

Carry Over Health care; requiring licensed practitioners to offer pharmacogenomic test prior to prescription of psychotropic drugs. Effective date.

Previously Filed As

OK SB217

Health care; requiring licensed practitioners to offer pharmacogenomic test prior to prescription of psychotropic drugs. Effective date.

OK SB929

Health care; requiring licensed practitioner to inform patient of certain information prior to administration of vaccine. Effective date.

OK SB403

Practice of psychology; allowing licensed psychologist to prescribe psychotropic drugs under certain conditions; providing for application for, issuance of, and expiration of certain certificates. Effective date.

OK SB32

Controlled dangerous substances; exempting certain practitioners from electronic prescription requirement. Effective date.

OK SB765

Practice of pharmacy; requiring wholesale distributors to provide for return of certain outdated prescription drugs; requiring prompt full credit to purchaser. Effective date.

OK SB513

Biomarker testing; requiring health insurance coverage of biomarker testing under certain conditions. Effective date.

OK HB2091

Public health and safety; decriminalizing certain drug testing strips; effective date.

OK SB887

Freedom of conscience; creating the Medical Ethics Defense Act; granting certain rights and protections to certain medical practitioners, healthcare institutions, or healthcare payers. Effective date.

OK SB768

Prescription drugs; establishing certain requirements relating to drug manufacturing and pricing. Effective date.

OK SB295

Controlled dangerous substances; requiring Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to establish certain procedures relating to central repository. Effective date.

Similar Bills

No similar bills found.